Sanofi (SNYNF) Other Accumulated Expenses (2009 - 2021)

Sanofi has reported Other Accumulated Expenses for 13 years, with the latest figure at $220.4 million in Q4 2021.

• Quarterly Other Accumulated Expenses rose 4.87% year-over-year to $220.4 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $220.4 million (up 4.87% YoY) and the FY2021 annual result came in at $228.0 million, up 13.29% from the prior year.
• Other Accumulated Expenses grew to $220.4 million in Q4 2021 per SNYNF's latest filing, from $210.2 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $10.8 billion in Q4 2017 and troughed at $161.3 million in Q4 2019.
• A 5-year average of $4.6 billion and a median of $220.4 million in 2021 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2017 and 2018: Other Accumulated Expenses soared 2193.52% in 2017, then slumped 98.13% in 2018.
• Over 5 years, Other Accumulated Expenses stood at $10.8 billion in 2017, then sank by 98.24% to $191.0 million in 2018, then decreased by 15.54% to $161.3 million in 2019, then jumped by 30.34% to $210.2 million in 2020, then rose by 4.87% to $220.4 million in 2021.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $220.4 million, $210.2 million, and $161.3 million for Q4 2021, Q4 2020, and Q4 2019 respectively.